Lawrence Korducki

1.0k total citations
39 papers, 841 citations indexed

About

Lawrence Korducki is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Complementary and alternative medicine. According to data from OpenAlex, Lawrence Korducki has authored 39 papers receiving a total of 841 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Pulmonary and Respiratory Medicine, 16 papers in Physiology and 6 papers in Complementary and alternative medicine. Recurrent topics in Lawrence Korducki's work include Chronic Obstructive Pulmonary Disease (COPD) Research (37 papers), Respiratory Support and Mechanisms (22 papers) and Asthma and respiratory diseases (16 papers). Lawrence Korducki is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (37 papers), Respiratory Support and Mechanisms (22 papers) and Asthma and respiratory diseases (16 papers). Lawrence Korducki collaborates with scholars based in United States, Canada and Germany. Lawrence Korducki's co-authors include Alan Hamilton, Gary T. Ferguson, Emílio Pizzichini, François Maltais, Matjaž Fležar, Lars Grönke, Roland Buhl, R Abrahams, Kay Tetzlaff and Andrea Koch and has published in prestigious journals such as American Journal of Respiratory and Critical Care Medicine, CHEST Journal and Journal of Allergy and Clinical Immunology.

In The Last Decade

Lawrence Korducki

38 papers receiving 825 citations

Peers

Countries citing papers authored by Lawrence Korducki

Since Specialization

Citations

This map shows the geographic impact of Lawrence Korducki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lawrence Korducki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lawrence Korducki more than expected).

Fields of papers citing papers by Lawrence Korducki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lawrence Korducki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lawrence Korducki. The network helps show where Lawrence Korducki may publish in the future.

Co-authorship network of co-authors of Lawrence Korducki

This figure shows the co-authorship network connecting the top 25 collaborators of Lawrence Korducki. A scholar is included among the top collaborators of Lawrence Korducki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lawrence Korducki. Lawrence Korducki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effect of Bronchodilation, Exercise Training, and Behavior Modification on Symptoms and Physical Activity in Chronic Obstructive Pulmonary Disease 2018 ·American Journal of Respiratory and Critical Care Medicine ·Thierry Troosters, François Maltais, Nancy Kline Leidy, Kim Lavoie, Maria Sedeno, Wim Janssens, Judith García‐Aymerich, Damijan Eržen, (unknown), Lawrence Korducki, Alan Hamilton, Jean Bourbeau	71
2	Effect of 8 and 12 weeks' once-daily tiotropium and olodaterol, alone and combined with exercise training, on exercise endurance during walking in patients with COPD 2017 ·Pneumologie ·Thierry Troosters, Jean Bourbeau, François Maltais, (unknown), Damijan Eržen, (unknown), Lawrence Korducki, (unknown), Wim Janssens, A. Hamilton	2
3	Enhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions: PHYSACTO randomised, placebo-controlled study design 2016 ·BMJ Open ·Thierry Troosters, Jean Bourbeau, François Maltais, Nancy Kline Leidy, Damijan Eržen, (unknown), Lawrence Korducki, Alan Hamilton	36
4	Pooled Safety Analysis Of Adjudicated Serious Adverse Events With The Fixed-Dose Combination Of Tiotropium + Olodaterol 2016 ·Pneumologie ·Thomas Köhnlein, Roland Buhl, Kay Tetzlaff, Lawrence Korducki, C. Franz Vogelmeier, (unknown)	1
5	Effect of Tiotropium + Olodaterol on the Use of Nighttime Rescue Medication in Patients With COPD: Results From Four Randomized, Double-Blind Studies 2015 ·CHEST Journal ·R Abrahams, Gary T. Ferguson, Emmanuelle Clerisme-Beaty, (unknown), Florian Voß, Lawrence Korducki, Nathan Bennett, Roland Buhl	1
6	Tiotropium + Olodaterol Provides Improvements in SGRQ and Dyspnea Compared With Monotherapy Components in Patients With COPD: Results From Four Randomized, Double-Blind Studies 2015 ·CHEST Journal ·Gary T. Ferguson, Emmanuelle Clerisme-Beaty, (unknown), Florian Voß, Lawrence Korducki, Nathan Bennett, R Abrahams	1
7	A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease 2015 ·Respiratory Medicine ·Guy Joos, (unknown), Carl Coeck, Lawrence Korducki, Alan Hamilton, Christina Kunz, René Aalbers	12
8	Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4) 2015 ·European Respiratory Journal ·Roland Buhl, François Maltais, R Abrahams, Leif Bjermer, Eric Derom, Gary T. Ferguson, Matjaž Fležar, Jacques Hébert, Lorcan McGarvey, Emílio Pizzichini, Jim Reid, Antony Veale, Lars Grönke, Alan Hamilton, Lawrence Korducki, Kay Tetzlaff, (unknown), Henrik Watz, Eric Bateman	245
9	Efficacy of Once-Daily Tiotropium and Olodaterol Maintenance Treatment for COPD: Patient-Reported Outcomes 2015 ·CHEST Journal ·François Maltais, (unknown), Lawrence Korducki, Roland Buhl	1
10	A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease 2015 ·Respiratory Medicine ·M. Reza Maleki-Yazdi, Ekkehard Beck, Alan Hamilton, Lawrence Korducki, Paul Koker, Charles Fogarty	14
11	Once-daily tiotropium and olodaterol fixed-dose combination via the respimat improves outcomes vs mono-components in COPD in two 1-year studies 2014 ·European Respiratory Journal ·Roland Buhl, Eric Derom, Gary T. Ferguson, François Maltais, Emílio Pizzichini, Jim Reid, Henrik Watz, (unknown), Alan Hamilton, Kay Tetzlaff, Lawrence Korducki, Holger Huisman, (unknown), Eric Bateman	2
12	Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies 2014 ·International Journal of COPD ·Andrea Koch, Emílio Pizzichini, Alan Hamilton, (unknown), Lawrence Korducki, Maria De Salvo, Pierluigi Paggiaro	79
13	The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2–4 COPD: results from two 6-week crossover studies 2014 ·SpringerPlus ·Gregory Feldman, Jonathan A. Bernstein, Alan Hamilton, Michael C. Nivens, Lawrence Korducki, Craig LaForce	34
14	Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studies 2014 ·International Journal of COPD ·Gary T. Ferguson, Gregory Feldman, Peter Hofbauer, Alan Hamilton, (unknown), Lawrence Korducki, (unknown)	63
15	Symptomatic benefit of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Combined analysis from two 48-week studies 2013 ·European Respiratory Journal ·Andrea Koch, Pierluigi Paggiaro, Alan Hamilton, (unknown), Lawrence Korducki, María Cristina De Salvo, Emílio Pizzichini	7
16	Pooled Safety Analysis of Olodaterol Once Daily via Respimat® Versus Placebo and Formoterol Twice Daily in Patients With COPD: Independently Adjudicated Respiratory-Related Serious Adverse Events 2013 ·CHEST Journal ·Dennis E. Niewoehner, Lorcan McGarvey, Alan Hamilton, Kay Tetzlaff, Lawrence Korducki, Claus Vogelmeier	1
17	48-week administration of olodaterol QD via Respimat® vs placebo and formoterol BID in patients with COPD: Pooled safety analysis 2013 ·European Respiratory Journal ·Lorcan McGarvey, Andrea Koch, (unknown), Alan Hamilton, Kay Tetzlaff, Lawrence Korducki, Gary T. Ferguson	4
18	Efficacy of Olodaterol Once Daily (QD) via Respimat in GOLD 2/3 COPD Patients Not Receiving Background Therapy: Pooled Data From 48-Week Studies 2013 ·CHEST Journal ·Gary T. Ferguson, (unknown), Alan Hamilton, Kay Tetzlaff, Lawrence Korducki, Andrea Koch	3
19	Four Weeks Once Daily Treatment with BI 1744 CL, a Novel Long-Acting ß ₂ -Agonist, Is Effective in COPD Patients. 2009 ·(unknown), Lawrence Korducki, (unknown), Paul Koker	17
20	Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease 2002 ·European Respiratory Journal ·J.A. van Noord, J.J. Smeets, Frank L. Custers, Lawrence Korducki, P. J. G. Cornelissen	72

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact